Claims for Patent: 7,758,889

Summary for Patent: 7,758,889

Title:	Fullerenes in targeted therapies
Abstract:	Herein we disclose a composition, comprising a C.sub.n-Ab, wherein C.sub.n is a fullerene or nanotube comprising n carbon atoms, and Ab is a moiety comprising an antigen-binding site and is linked to the Cn. The composition can further comprise a therapeutic molecule associated with the C.sub.n-Ab. Also, we disclose a method of treating a disease in a mammal, comprising administering to the mammal an effective amount of the composition.
Inventor(s):	Sagman; Uri (Toronto, CA), Rosenblum; Michael G. (Sugar Land, TX), Wilson; Lon J. (Houston, TX)
Assignee:	Luna Innovations Incorporated (Roanoke, VA)
Application Number:	10/623,110
Patent Claims:	1. A composition, comprising: (i) a C.sub.n-Ab, wherein C.sub.n is a fullerene or nanotube comprising n carbon atoms, and Ab is a moiety comprising an antigen-binding site and is covalently linked to the C.sub.n, wherein the antigen-binding site recognizes an antigen associated with a medical condition; and (ii) a pharmaceutically-acceptable carrier. 2. The composition of claim 1, wherein the C.sub.n is substituted with one or more water-solubilizing groups. 3. The composition of claim 1, wherein the Ab comprises an antigen-binding site selected from ZME-018, SCFVMEL, dSCFVMEL, GD2, HuM195, herceptin, BACH 250, ML 3-9, C 6.5, or .alpha.MMP9. 4. The composition of claim 1, further comprising a therapeutic molecule associated with the C.sub.n-Ab. 5. The composition of claim 4, wherein the therapeutic molecule is covalently bound to the C.sub.n. 6. The composition of claim 4, wherein the C.sub.n is substituted with a polar group and the therapeutic molecule is associated with the polar group. 7. The composition of claim 4, wherein the therapeutic molecule is paclitaxel, doxorubicin, vincristine, or cisplatin. 8. A method of treating a disease in a mammal, comprising: administering to the mammal an effective amount of a composition comprising (i) a C.sub.n-Ab, wherein C.sub.n is a fullerene or nanotube comprising n carbon atoms, and Ab is a moiety comprising an antigen-binding site and is covalently linked to the C.sub.n, wherein the antigen-binding site recognizes an antigen associated with the disease, and (ii) a pharmaceutically-acceptable carrier. 9. The method of claim 8, the C.sub.n is substituted with one or more water-solubilizing groups. 10. The method of claim 8, wherein the Ab comprises an antigen-binding site selected from ZME-018, SCFVMEL, dSCFVMEL, GD2, HuM195, herceptin, BACH 250, ML 3-9, C 6.5, or .alpha.MMP9. 11. The method of claim 8, wherein the disease is an oxidative stress disease. 12. The method of claim 8, wherein the composition is administered at a dosage of from about 0.001 mg C.sub.n per kg body weight per day to about 1 g C.sub.n per kg body weight per day. 13. The method of claim 8, wherein the composition further comprises a therapeutic molecule associated with the C.sub.n-Ab. 14. The method of claim 13, wherein the therapeutic molecule is paclitaxel, doxorubicin, vincristine, or cisplatin. 15. The method of claim 13, wherein the composition is administered at a dosage of from about 0.001 mg therapeutic molecule per kg body weight per day to about 1 g therapeutic molecule per kg body weight per day. 16. The method of claim 8, wherein the method further comprises administering an adjuvant to the mammal, wherein the adjuvant dissociates the therapeutic molecule from the C.sub.n-Ab.

Details for Patent 7,758,889

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	September 25, 1998		2023-07-18
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	February 10, 2017		2023-07-18